Geller Biopharm Represents ViralClear Financing for Phase II Ready Treatment for Covid-19

Apr 23, 2020
1 min read

Geller Biopharm represented ViralClear in financing work connected to a potential COVID-19 treatment prepared for Phase II testing.

Originally listed in the Pickwick Capital Partners News archive. This migration copy uses a concise summary rather than the complete original article text.

Recent Posts

See All

Another insightful market perspective from John B. Levy & Company, Stuck in Second Gear, examines persistently elevated interest rates and their impact on commercial real estate financing, acquisition

Congratulations to Hummingbird Bioscience on winning the Asia Pacific Trailblazer Award at the 2026 Nebius AI Discovery Awards

Hummingbird Bioscience received the Asia Pacific Trailblazer Award at the 2026 Nebius AI Discovery Awards for its work applying artificial intelligence to biotherapeutic discovery.

Another insightful commentary from Cedars Hill Group, CHG Issue #229, The Return of the Wrecking Ball, examines the return of dollar strength, shifting liquidity conditions, and their impact on mar...

Cedars Hill Group reviews renewed U.S. dollar strength, changing liquidity conditions, and the resulting implications for markets, artificial intelligence, commercial real estate, and geopolitics.